Pustular Psoriasis: Recognizing and Treating A Rare But Serious Disease

PROGRAM DESCRIPTION Pustular psoriasis is a group of rare psoriasis subtypes typified by aseptic, neutrophil-rich pustules. The three most common types are generalized pustular psoriasis, palmoplantar pustular psoriasis, and acrodermatitis continua of Hallopeau. The diagnosis of pustular psoriasis relies primarily on clinical features and may be difficult. Recent guidelines on diagnosis, classification, and assessment of severity have been published by ERASPEN and by the Japanese Dermatological Association. Treatment of pustular psoriasis involves systemic therapy with cyclosporine, methotrexate or acitretin. Guidelines and a treatment algorithm have been published by the Japanese Dermatological Association. The understanding that IL-36 cytokines are likely the key driver of the autoimmune response in pustular psoriasis has led to the development of two novel, investigational monoclonal antibodies that target the IL-36 receptor. In addition, agents that target other molecules have also been investigated. Diagnosing and Managing Pustular Psoriasis: A Rare But Serious Disease will provide clinicians with information about the most recent guidelines for diagnosing, classifying, and assessing the severity of pustular psoriasis. Current treatment guidelines and a review of agents in development will help clinicians manage this rare group of disorders. AGENDA Welcome and Introduction Diagnosing and Assessing Severity of Pustular Psoriasis Managing Pustular Psoriasis Q&A Session and Activity Roundup

PROGRAM FACULTY

M. Susan Burke, MD, FACP

Clinical Associate Professor of Medicine

Sidney Kimmel Medical College at Thomas Jefferson University

Philadelphia,

PA Senior Advisor, Lankenau Medical Associates

Lankenau Medical Center

Wynnewood, PA

Ahuva Cices, MD

Dermatology Resident

Icahn School of Medicine at Mount Sinai

New York, NY

Mark Lebwohl, MD

Dean for Clinical Therapeutics

Emeritus of the Kimberly and Eric J. Waldman

Department of Dermatology

Icahn School of Medicine at Mount Sinai

New York, NY

TARGET AUDIENCE

The intended audience for this educational initiative is primary care physicians and other clinicians who may diagnose and manage patients with pustular psoriasis.

EDUCATIONAL OBJECTIVES At the conclusion of this education, participants should be able to:

• Describe the pathophysiology of pustular psoriasis and how it is different from that of plaque psoriasis
• Use current guidelines to diagnose and classify pustular psoriasis
• Employ current guidelines when managing patients with pustular psoriasis
• Assess the mechanism of action, efficacy, and safety of agents in development for managing pustular psoriasis

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION STATEMENT

The Potomac Center for Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For information about the accreditation of this program, please email: contact@potomacme.org.

ABIM MOC RECOGNITION STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through PCME’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

AMERICAN BOARD OF DERMATOLOGY MOC INFORMATION

Dermatologists certified by the American Board of Dermatology (ABD) must earn a minimum of 25 hours of AMA PRA Category 1 Credits™ annually. Half of these credits must be Dermatology practice-specific CME credits from accredited organizations in order to fulfill the lifelong learning component of MOC. Participation in this activity will support board certified dermatologists in contributing towards this MOC requirement set forth by the ABD.

MOC APPROVAL STATEMENT

Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, “Diagnosing and Managing Pustular Psoriasis: A Rare But Serious Disease” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: MOC Part II CME Activity Family Medicine

DISCLOSURE INFORMATION The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

Program Faculty

The faculty, authors and content developers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

M. Susan Burke, MD, FACP: Speaker’s Bureau: Merck and Co, Inc.

Ahuva Cices, MD: Nothing to disclose

Mark Lebwohl, MD Grant/Research Support: AbbVie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc.; Consultant/Independent Contractor: Aditum Bio, Almirall, AnaptysBio, Arcutis, Inc., Aristea Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr. Reddy’s Laboratories, Evelo Biosciences, Evommune, Inc., Facilitatation of International Dermatology Education, Forte Biosciences, Helsinn Therapeutics, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Verrica; Speaker’s Bureau: Aimmune

Planners and Managers

The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Chad Williamson, MS, MBA, CMPP: Nothing to disclose

Content Reviewers The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Katie Propst, PhD: Nothing to disclose

FDA DISCLOSURE The contents of some CME/MOC activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

HARDWARE/SOFTWARE REQUIREMENTS Please ensure the computer system you plan to use meets the following minimum requirements:

• Operating System: Windows 98 or higher & Macintosh 2.2 or higher
• Internet Browser (Mac & Windows): Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
• Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
• Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/CNE/CPE CREDIT AND MOC POINTS There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME/MOC activity in its entirety, and then complete the post-test, with a score of 80% or better, and evaluation. The estimated time for completion of this activity is 1 hour. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test. Participant is allowed to take the post-test multiple times.

Jointly provided by the Potomac Center for Medical Education and Rockpointe

In collaboration with the National Psoriasis Foundation

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. Click here for the PCME Privacy Policy